ADX106772 / Addex - LARVOL DELTA

ADX106772, an mGlu2 Receptor Positive Allosteric Modulator, Selectively Attenuates Oxycodone- but not Sweetened Condensed Milk-Seeking Behavior (CPDD 2024) - "ADX106772 reduced oxycodone taking and seeking and showed a lack of effect on the motivation to consume and seek a palatable conventional reinforcer, supporting the mGluR2 positive allosteric modulation approach as a potential treatment of prescription OUD."

Addiction (Opioid and Alcohol) • Substance Abuse

ADX106772, an mGlu2 receptor positive allosteric modulator, selectively attenuates oxycodone taking and seeking. (PubMed, Neuropharmacology) - "ADX106772 reduced oxycodone self-administration and conditioned reinstatement without affecting SCM self-administration or conditioned reinstatement. ADX106772 reduced oxycodone taking and seeking and did not affect the motivation for the palatable conventional reinforcer, suggesting that activating mGlu2 receptors with a positive allosteric modulator is a potential approach for prescription OUD treatment."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

ADX106772, an mGlu2 receptor positive allosteric modulator, selectively attenuates oxycodone- but not sweetened condensed milk-seeking behavior (Neuroscience 2022) - "ADX106772 reduced oxycodone taking and seeking and showed a lack of effect on the motivation to consume and seek a palatable conventional reinforcer, supporting the mGluR2 positive allosteric modulation approach as a potential treatment of prescription OUD. ADX106772 was supplied by Addex Therapeutics."

Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Substance Abuse